·On Sept. 22, the U.S. Food and Drug Administration (FDA) approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with…
On Sept. 4, the U.S. Food and Drug Administration (FDA) approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary orotic aciduria,…
On Aug. 18, the U.S. Food and Drug Administration (FDA) approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.…
On July 24, the U.S. Food and Drug Administration (FDA) approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of…
On July 13, the U.S. Food and Drug Administration (FDA) approved Rexulti (brexpiprazole) to treat adults with schizophrenia and as an add-on treatment to…
On July 2, the U.S. Food and Drug Administration (FDA) approved Orkambi (lumacaftor 200 mg/ivacaftor 125 mg) for the treatment of cystic fibrosis (CF)…
On Sept. 4, the U.S. Food and Drug Administration (FDA) approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary…
On Aug. 18, the U.S. Food and Drug Administration (FDA) approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder in…
On July 24, the U.S. Food and Drug Administration (FDA) approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new…